JP2021517164A5 - - Google Patents
Info
- Publication number
- JP2021517164A5 JP2021517164A5 JP2020570407A JP2020570407A JP2021517164A5 JP 2021517164 A5 JP2021517164 A5 JP 2021517164A5 JP 2020570407 A JP2020570407 A JP 2020570407A JP 2020570407 A JP2020570407 A JP 2020570407A JP 2021517164 A5 JP2021517164 A5 JP 2021517164A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014959A JP2024032976A (ja) | 2018-03-05 | 2024-02-02 | アデノシン受容体アンタゴニストおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638737P | 2018-03-05 | 2018-03-05 | |
| US62/638,737 | 2018-03-05 | ||
| US201862688088P | 2018-06-21 | 2018-06-21 | |
| US62/688,088 | 2018-06-21 | ||
| PCT/US2019/020810 WO2019173380A1 (en) | 2018-03-05 | 2019-03-05 | Adenosine receptor antagonists and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014959A Division JP2024032976A (ja) | 2018-03-05 | 2024-02-02 | アデノシン受容体アンタゴニストおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517164A JP2021517164A (ja) | 2021-07-15 |
| JP2021517164A5 true JP2021517164A5 (enExample) | 2022-04-01 |
| JP7849948B2 JP7849948B2 (ja) | 2026-04-22 |
Family
ID=67847428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570407A Active JP7849948B2 (ja) | 2018-03-05 | 2019-03-05 | アデノシン受容体アンタゴニストおよびその使用 |
| JP2024014959A Withdrawn JP2024032976A (ja) | 2018-03-05 | 2024-02-02 | アデノシン受容体アンタゴニストおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014959A Withdrawn JP2024032976A (ja) | 2018-03-05 | 2024-02-02 | アデノシン受容体アンタゴニストおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210040097A1 (enExample) |
| EP (2) | EP3762386B1 (enExample) |
| JP (2) | JP7849948B2 (enExample) |
| KR (1) | KR102754522B1 (enExample) |
| CN (1) | CN112218867B (enExample) |
| AU (2) | AU2019232736B2 (enExample) |
| BR (1) | BR112020018158A2 (enExample) |
| ES (1) | ES2975753T3 (enExample) |
| IL (1) | IL277144B2 (enExample) |
| MX (1) | MX2020009286A (enExample) |
| SG (1) | SG11202008611UA (enExample) |
| WO (1) | WO2019173380A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020009286A (es) | 2018-03-05 | 2020-12-11 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos. |
| WO2022032091A1 (en) * | 2020-08-07 | 2022-02-10 | Teon Therapeutics, Inc. | Combination therapy with adenosine receptor antagonists |
| CN116322698A (zh) * | 2020-09-04 | 2023-06-23 | 泰昂治疗公司 | 腺苷a2b受体拮抗剂的共晶 |
| WO2022256550A1 (en) | 2021-06-04 | 2022-12-08 | Teon Therapeutics, Inc. | Crystalline forms of an adenosine a2b receptor antagonist |
| TW202327612A (zh) * | 2021-09-10 | 2023-07-16 | 美商天恩治療有限公司 | 使用腺苷受體拮抗劑之改良療法 |
| US20260015356A1 (en) * | 2022-07-14 | 2026-01-15 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| WO2026035860A1 (en) | 2024-08-07 | 2026-02-12 | Teon Therapeutics, Inc. | Formulations of adenosine receptor antagonist |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466811A (en) * | 1994-07-18 | 1995-11-14 | Merck & Co., Inc. | Dioxolenylmethyl carbamates pro moieties for amine drugs |
| EP1075472A1 (en) | 1998-04-15 | 2001-02-14 | Warner-Lambert Company | Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| ATE520694T1 (de) | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
| US20080318983A1 (en) | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| GEP20074230B (en) | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| CA2524778C (en) * | 2003-05-06 | 2013-01-29 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| US20060058322A1 (en) * | 2004-09-01 | 2006-03-16 | Dewan Zeng | Method of wound healing using A2B adenosine receptor antagonists |
| EP1799221A1 (en) | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| NZ564326A (en) * | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| WO2007109547A2 (en) | 2006-03-17 | 2007-09-27 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| US20100254965A1 (en) | 2006-10-24 | 2010-10-07 | Board Of Regents ,The University Of Texas System | Adenosine Signaling in Diagnosis, Treatment, and Prevention of Priapism and Erectile Dysfunction |
| WO2009088518A1 (en) | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| JP5460690B2 (ja) * | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| WO2009157938A1 (en) | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| US20120003329A1 (en) | 2010-06-30 | 2012-01-05 | Gilead Sciences, Inc. | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension |
| CN103261200B (zh) * | 2010-09-13 | 2016-03-30 | 阿迪维纳斯疗法有限公司 | 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途 |
| AR085942A1 (es) * | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| WO2012170209A2 (en) * | 2011-05-23 | 2012-12-13 | Nectid, Inc. | Benzofuran-2 carboxamide compounds |
| US10117868B2 (en) | 2011-10-25 | 2018-11-06 | Case Western Reserve University | Systems pharmacology for treating ocular disorders |
| EP3668517A4 (en) | 2017-08-14 | 2021-02-17 | Phosphorex, Inc. | Microparticle formulations of adenosine receptor antagonists for treating cancer |
| EP3727371A4 (en) | 2017-12-19 | 2021-10-27 | GPCR Therapeutics, Inc. | GPCR HETEROMER INHIBITORS AND THEIR USES |
| MX2020009286A (es) | 2018-03-05 | 2020-12-11 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos. |
-
2019
- 2019-03-05 MX MX2020009286A patent/MX2020009286A/es unknown
- 2019-03-05 IL IL277144A patent/IL277144B2/en unknown
- 2019-03-05 BR BR112020018158-7A patent/BR112020018158A2/pt unknown
- 2019-03-05 CN CN201980030563.6A patent/CN112218867B/zh active Active
- 2019-03-05 AU AU2019232736A patent/AU2019232736B2/en active Active
- 2019-03-05 KR KR1020207028522A patent/KR102754522B1/ko active Active
- 2019-03-05 EP EP19764343.0A patent/EP3762386B1/en active Active
- 2019-03-05 WO PCT/US2019/020810 patent/WO2019173380A1/en not_active Ceased
- 2019-03-05 US US16/978,040 patent/US20210040097A1/en not_active Abandoned
- 2019-03-05 JP JP2020570407A patent/JP7849948B2/ja active Active
- 2019-03-05 ES ES19764343T patent/ES2975753T3/es active Active
- 2019-03-05 EP EP24152200.2A patent/EP4364727A3/en active Pending
- 2019-03-05 SG SG11202008611UA patent/SG11202008611UA/en unknown
-
2021
- 2021-02-02 US US17/165,736 patent/US11124515B2/en active Active
- 2021-08-02 US US17/391,245 patent/US20220056033A1/en not_active Abandoned
-
2024
- 2024-02-02 JP JP2024014959A patent/JP2024032976A/ja not_active Withdrawn
- 2024-06-28 AU AU2024204483A patent/AU2024204483B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517164A5 (enExample) | ||
| JP7515481B2 (ja) | Ｉｌ－１７の小分子調節物質としてのアミノ酸アニリド | |
| JP2024050527A5 (enExample) | ||
| JP2022512482A5 (enExample) | ||
| CN113614080A (zh) | Kras g12c抑制剂化合物及其用途 | |
| KR101927114B1 (ko) | 치료 화합물 및 조성물 | |
| JP2021511331A5 (enExample) | ||
| JP2022532706A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2022544714A5 (enExample) | ||
| TW201431865A (zh) | 硼酸衍生物及其治療用途 | |
| WO2021078274A1 (zh) | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 | |
| JP6672296B2 (ja) | 強力なγ−セクレターゼモジュレータ | |
| CN103664897A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| EP3992176B1 (en) | Ep2 antagonist | |
| CN102361868A (zh) | 作为1-磷酸-鞘氨醇激动剂的吡唑-1，2，4-噁二唑衍生物 | |
| JP2013542267A5 (enExample) | ||
| JP2023516235A5 (enExample) | ||
| JP2022119852A5 (enExample) | ||
| JP2020518571A5 (enExample) | ||
| CN111278809A (zh) | 二环砜类和亚砜类、以及其使用方法 | |
| TW202241399A (zh) | Ｅｐ受體拮抗藥與免疫檢查點抑制藥及／或ｅｐ受體拮抗藥之組合 | |
| JP2022552019A5 (enExample) | ||
| JP2022554330A5 (enExample) |